Investigational drug study for Hepatocellular Carcinoma
Catherine Frenette, MD
This study is looking at treating patients with advanced liver cancer using an immunotherapy drug called atezolizumab, in combination with a chemotherapy drug called cabozantinib. Atezolizumab works to stimulate the immune system to destroy cancer cells. Cabozantinib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Study subjects will be assigned by chance to receive one of 3 treatments: a combination of cabozantinib and atezolizumab, only cabozantinib or only sorafenib, which is the current chemotherapy treatment for liver cancer.
Be 18 years of age or older
Have been diagnosed with hepatocellular carcinoma
Not be eligible for curative treatment such as a transplant, surgery or ablation therapy or localized therapy such as TACE
Have received prior systemic therapy such as chemotherapy, small molecule kinase inhibitors and immune checkpoint inhibitors
Have been diagnosed with fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma
Have been diagnosed with hepatic encephalopathy or require medication for prevention or control of encephalopathy within 6 months
Have clinically meaningful ascites (ascites requiring treatment) within 6 months
All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.